Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | CTSH | P09668 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6371397 | 0.79 | CCR1 (0.36) | CCR1RAB9ACCR5OPRK1KMT2A | |
| SCHEMBL20687488 | 0.78 | KMT2A (0.35) | KMT2A | |
| SCHEMBL11901636 | 0.78 | KDM4E (0.44) | CCR1RAB9ACCR5OPRK1KMT2A | |
| SCHEMBL16705096 | 0.77 | KMT2A (0.50) | CCR1RAB9ACCR5OPRK1KMT2A | |
| SCHEMBL737630 | 0.74 | CCR1 (0.41) | CCR1RAB9ACCR5OPRK1KMT2A | |
| SCHEMBL22222353 | 0.73 | CCR1 (0.40) | CCR1RAB9ACCR5OPRK1KMT2A | |
| SCHEMBL9906403 | 0.72 | CCR1 (0.37) | CCR1RAB9ACCR5 | |
| SCHEMBL24446496 | 0.71 | KMT2A (0.41) | CCR1RAB9ACCR5OPRK1KMT2A | |
| SCHEMBL3462526 | 0.71 | KMT2A (0.62) | CCR1RAB9ACCR5OPRK1KMT2A | |
| SCHEMBL13437131 | 0.71 | KDM4E (0.56) | CCR1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9029377-B2 | Platelet-activating factor receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20120108595-A1 | PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108595-A1 | PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS | PTAFR, PAFAH1B2, PAFAH1B3 | CCR1 1062/4885RAB9A 2153/4885CCR5 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.